Vijendra Swarup is a Cardiology physician. OpenAlex indexes 38 publications with 771 citations (h-index 11); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1848 E Thomas Rd Ste 100
Phoenix, AZ 850168112
Telephone
602-456-2342Registry record last updated 21 Jul 2022.
Clinical trials
- CARTO® 3 System and Real Time Intracardiac Ultrasound
Sponsor: Biosense Webster, Inc.
- NAVISTAR® THERMOCOOL® SF Catheter: Observational Study
Sponsor: Biosense Webster, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biosense Webster, Inc.Program year202567 payments
- Abbott LaboratoriesProgram year202541 payments
- Boston Scientific CorporationProgram year20259 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86%Beta blocker20.4%Sotalol44%Metoprolol Succinate35%Carvedilol14%Metoprolol Tartrate5%Atenolol3%Part D≥196 patientsStatin15.6%Rosuvastatin Calcium62%Atorvastatin Calcium34%Simvastatin3%Pravastatin Sodium1%Part D<11 patients+ 16 more classes in this area
Blood & clotting
8.6%Factor Xa inhibitor6.3%Eliquis81%Xarelto19%Part D≥131 patientsP2Y12 inhibitor1.6%Clopidogrel100%Part D≥41 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.9%SGLT2 inhibitor3%Jardiance51%Farxiga49%Part D≥41 patientsPotassium supplement0.9%Potassium Chloride100%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”